Anti –programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study
This study investigated the tolerability and efficacy of anti –programmed death ligand 1 (PD (L)1) immunotherapies in patients with pre-existing SSc.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Marion Panhaleux, Olivier Espitia, Benjamin Terrier, Guillaume Manson, Alexandre Maria, S ébastien Humbert, Benoît Godbert, Julie Perrin, Aurélie Achille, Jennifer Arrondeau, Marie Kostine, Vincent Fallet, Grégory Pugnet, Benjamin Chaigne, Stéphane C Tags: Original Research Source Type: research
More News: Autoimmune Disease | Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Scleroderma | Study